```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1         Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2         "Ask CAS" for self-help around the clock
 NEWS  3  May 12  EXTEND option available in structure searching
 NEWS  4  May 12  Polymer links for the POLYLINK command completed in REGISTRY
 NEWS  5  May 27  New UPM (Update Code Maximum) field for more efficient patent
                  SDIs in CAplus
 NEWS  6  May 27  CAplus super roles and document types searchable in REGISTRY
 NEWS  7  Jun 28  Additional enzyme-catalyzed reactions added to CASREACT
 NEWS  8  Jun 28  ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
                  and WATER from CSA now available on STN(R)
 NEWS  9  Jul 12  BEILSTEIN enhanced with new display and select options,
                  resulting in a closer connection to BABS
 NEWS 10  Jul 30  BEILSTEIN on STN workshop to be held August 24 in conjunction
                  with the 228th ACS National Meeting
 NEWS 11  AUG 02  IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                  fields
 NEWS 12  AUG 02  CAplus and CA patent records enhanced with European and Japan
                  Patent Office Classifications
 NEWS 13  AUG 02  STN User Update to be held August 22 in conjunction with the
                  228th ACS National Meeting
 NEWS 14  AUG 02  The Analysis Edition of STN Express with Discover!
                  (Version 7.01 for Windows) now available
 NEWS 15  AUG 04  Pricing for the Save Answers for SciFinder Wizard within
                  STN Express with Discover! will change September 1, 2004
 NEWS 16  AUG 27  BIOCOMMERCE: Changes and enhancements to content coverage
 NEWS 17  AUG 27  BIOTECHABS/BIOTECHDS: Two new display fields added for legal
                  status data from INPADOC
 NEWS 18  SEP 01  INPADOC: New family current-awareness alert (SDI) available
 NEWS 19  SEP 01  New pricing for the Save Answers for SciFinder Wizard within
                  STN Express with Discover!
 NEWS 20  SEP 01  New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
 NEWS 21  SEP 14  STN Patent Forum to be held October 13, 2004, in Iselin, NJ

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

```
  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:39:24 ON 21 SEP 2004

=> fil reg
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:39:34 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    20 SEP 2004  HIGHEST RN 748739-98-2
DICTIONARY FILE UPDATES:   20 SEP 2004  HIGHEST RN 748739-98-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10684746.str
```





chain nodes :
9 10 11 12 13 17 18 19 20 21 22 23 24 25 26 27 32 33 36 37 38
40
ring nodes :
1 2 3 4 5 6 7 8 14 15 16 28 29 30 31 34 35 39 41 42 43 44 45
chain bonds :
1-27 4-10 5-9 6-32 8-37 10-11 11-12 11-13 14-17 16-18 18-19 19-20 19-26
20-21 20-25 21-22 22-23 23-24 28-33 31-36 37-38 38-39 38-40
ring bonds :
1-2 1-8 1-15 2-3 3-4 3-14 4-5 5-6 6-7 6-28 7-8 7-31 14-16 15-16 28-29
29-30 30-31 30-34 31-35 34-35 39-41 39-45 41-42 42-43 43-44 44-45
exact/norm bonds :
1-2 1-8 1-15 1-27 2-3 3-4 3-14 4-5 4-10 5-6 5-9 6-7 6-28 7-8 7-31
8-37 10-11 11-12 11-13 14-16 15-16 16-18 18-19 19-26 20-25 21-22 22-23
23-24 28-29 28-33 29-30 30-31 30-34 31-35 31-36 34-35 37-38 38-40
exact bonds :
6-32 14-17 19-20 20-21 38-39
normalized bonds :
39-41 39-45 41-42 42-43 43-44 44-45

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS 33:CLASS 34:Atom 35:Atom
36:CLASS 37:CLASS 38:CLASS 39:Atom 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom
45:Atom

```
L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 10:39:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      8 TO ITERATE

100.0% PROCESSED       8 ITERATIONS                            3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            8 TO      329
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:39:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    180 TO ITERATE

100.0% PROCESSED     180 ITERATIONS                           44 ANSWERS
SEARCH TIME: 00.00.01

L3           44 SEA SSS FUL L1

=> s l3 and caplus/lc
      39041690 CAPLUS/LC
L4          44 L3 AND CAPLUS/LC

=> fil caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   159.85     160.06

FILE 'CAPLUS' ENTERED AT 10:40:02 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.
```

```
FILE COVERS 1907 - 21 Sep 2004  VOL 141 ISS 13
FILE LAST UPDATED: 20 Sep 2004  (20040920/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l4
L5            19 L4

=> d ibib abs hitstr 1-19
```

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2003:427763 CAPLUS
DOCUMENT NUMBER:	139:350856
TITLE:	Structure-activity relationship study of taxoids for their ability to activate murine macrophages as well as inhibit the growth of macrophage-like cells
AUTHOR(S):	Ojima, Iwao; Fumero-Oderda, Cecilia L.; Kuduk, Scott D.; Ma, Zhuping; Kirikae, Fumiko; Kirikae, Teruo
CORPORATE SOURCE:	Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA
SOURCE:	Bioorganic & Medicinal Chemistry (2003), 11(13), 2867-2888 CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 139:350856

AB A series of new taxoids modified at the C-3', C-3'N, C-10, C-2 and C-7 positions was designed, synthesized and evaluated for their potency to induce NO and TNF production by peritoneal murine macrophages (Mϕ) from LPS-responsive C3H/HeN and LPS-hyporesponsive C3H/HeJ strains and human blood cells, and for their ability to inhibit the growth of Mϕ-like cell lines J774.1 and J7.DEF3. The SAR-study showed that the nature of the substituents at these positions are critical for the induction of TNF and NO production by Mϕ. Positions C-3' and C-10 are the most flexible, and an intriguing effect of the length of the substituents at the C-10 position is observed for taxoids bearing a straight chain alkanoyl moiety. An aromatic group at the C-3'N and C-2 positions is required for the activity, while only hydroxyl or acetyl substituents seem to be tolerated at the C-7 position. The natural stereochem. in the C-13 isoserine side chain of the taxoids is an absolute requirement for macrophage activation. There is no correlation between the ability of the taxoids to induce TNF/NO production in C3H/HeN Mϕ and the cytotoxicity against Mϕ-like cells.

IT **160084-79-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of taxoids and their ability to activate murine macrophages and inhibition of the growth of macrophage-like cells)

RN 160084-79-7 CAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2002:931582 CAPLUS
DOCUMENT NUMBER:	139:46375
TITLE:	Investigation of structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA
AUTHOR(S):	Islam, Mohd N.; Song, Yuqing; Iskander, Magdy N.
CORPORATE SOURCE:	Victorian College of Pharmacy, Department of Medicinal Chemistry, Monash University, Parkville, 3052, Australia
SOURCE:	Journal of Molecular Graphics & Modelling (2003), 21(4), 263-272 CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER:	Elsevier Science Inc.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB CoMFA and CoMSIA anal. were utilized in this investigation to define the important interacting regions in paclitaxel/tubulin binding site and to develop selective paclitaxel-like active compds. The starting geometry of paclitaxel analogs was taken from the crystal structure of docetaxel. A total of 28 derivs. of paclitaxel were divided into two groups-a training set comprising of 19 compds. and a test set comprising of nine compds. They were constructed and geometrically optimized using SYBYL v6.6. CoMFA studies provided a good predictability (q2=0.699, r2=0.991, PC=6, S.E.E.=0.343 and F=185.910). They showed the steric and electrostatic properties as the major interacting forces while the lipophilic property contribution was a minor factor for recognition forces of the binding site. These results were in agreement with the exptl. data of the binding activities of these compds. Five fields in CoMSIA anal. (steric, electrostatic, hydrophobic, hydrogen-bond acceptor and donor properties) were considered contributors in the ligand-receptor interactions. The results obtained from the CoMSIA studies were: q2=0.535, r2=0.983, PC=5, S.E.E.=0.452 and F=127.884. The data obtained from both CoMFA and CoMSIA studies were interpreted with respect to the paclitaxel/tubulin binding site. This intuitively suggested where the most significant anchoring points for binding affinity are located. This information could be used for the development of new compds. having paclitaxel-like activity with new chemical entities to overcome the existing pharmaceutical barriers and the economical problem associated with the synthesis of the paclitaxel analogs. These will boost the wide use of this useful class of compds., i.e. in brain tumors as the most of the present active compds. have poor blood-brain barrier crossing ratios and also, various tubulin isotypes has shown resistance to taxanes and other antimitotic agents.

IT **178250-25-4 181706-26-3 181706-27-4**
181706-30-9 545389-76-2

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structural requirements of anticancer activity at the paclitaxel/tubulin binding site using CoMFA and CoMSIA)

RN 178250-25-4 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-26-3 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(diethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181706-27-4 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[(methylamino)carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-30-9 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[[(1-methylethyl)amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 545389-76-2 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:748811 CAPLUS
DOCUMENT NUMBER: 137:247836
TITLE: Preparation of taxoid antitumor agents
INVENTOR(S): Ojima, Iwao
PATENT ASSIGNEE(S): The Research Foundation of State University of New York, USA
SOURCE: U.S., 18 pp., Cont.-in-part of U. S. 6,100,411. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	US 6458976	B1	20021001	US 1999-457332		19991209
	US 6100411	A	20000808	US 1996-608003		19960304
PRIORITY APPLN. INFO.:				US 1994-330956	B2	19941028
				US 1996-608003	A2	19960304

OTHER SOURCE(S): MARPAT 137:247836
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Taxoids of formula I [R1 = branched or unbranched C3-C5 alkyl or alkenyl, CF2H, (S)-2,2-dimethylcyclopropyl; R2 = C1-C4 alkyl; R3 = F, Cl, OMe, vinyl, Me, N3] are prepared as antitumor agents. Thus, II was prepared and had IC50 of 0.9 nM against human breast carcinoma.

IT **178250-25-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of taxoid antitumor agents)
RN 178250-25-4 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **178250-29-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of taxoid antitumor agents)
RN 178250-29-8 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L5   ANSWER 4 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:143290  CAPLUS
DOCUMENT NUMBER:          136:183968
TITLE:                    Preparation of taxoid anti-tumor agents and
                          pharmaceutical compositions thereof
INVENTOR(S):              Ojima, Iwao
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.
                          6,100,411.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   5
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     US 2002022651        A1    20020221    US 2001-822842         20010402
     US 6500858           B2    20021231
     US 6100411           A     20000808    US 1996-608003         19960304
     WO 2002078690        A2    20021010    WO 2002-US9865         20020402
     WO 2002078690        A3    20021121
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003232878        A1    20031218    US 2002-330535         20021230
PRIORITY APPLN. INFO.:                      US 1994-330956      B2 19941028
                                            US 1996-608003      A2 19960304
                                            US 2001-822842      A  20010402
OTHER SOURCE(S):          MARPAT 136:183968
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pharmaceutical compns., methods of administration, and methods of treatment of cancer with new generation taxoids, of formulas (I) and (II), and derivs. thereof, are described. The compds. have strong antitumor activity against drug-resistant tumors. Thus, II (SB-T-1213) was prepd from III and 7-triethylsilyl-10-propanoyl-10-deacetylbaccatin III (prepns. given). SB-T-1213 was active at 19 mg/kg/adm dosage to B16/TXT melanoma-bearing mice.

IT **178250-25-4P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of taxoid antitumor agents)

RN 178250-25-4 CAPLUS

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **178250-29-8P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of taxoid antitumor agents)

RN 178250-29-8 CAPLUS

CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



```
L5   ANSWER 5 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2001:581884  CAPLUS
DOCUMENT NUMBER:          135:166940
TITLE:                    Preparation of C10 carbamoyloxy substituted taxanes as
                          antitumor agents
INVENTOR(S):              Holton, Robert A.; Fang, Weishuo
PATENT ASSIGNEE(S):       Florida State University Research Foundation, Inc.,
                          USA
SOURCE:                   PCT Int. Appl., 72 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   9
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2001057033        A1    20010809    WO 2001-US3633         20010202
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001033313        A5    20010814    AU 2001-33313          20010202
     BR 2001004352        A     20020102    BR 2001-4352           20010202
     EP 1165551           A1    20020102    EP 2001-905434         20010202
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     US 2002052403        A1    20020502    US 2001-776426         20010202
     US 6638973           B2    20031028
     US 2002077341        A1    20020620    US 2001-775852         20010202
     US 6596737           B2    20030722
     JP 2003522173        T2    20030722    JP 2001-557865         20010202
     NO 2001004760        A     20011130    NO 2001-4760           20011001
     US 2004034230        A1    20040219    US 2003-618063         20030711
     US 2004097579        A1    20040520    US 2003-680649         20031007
PRIORITY APPLN. INFO.:                      US 2000-179793P     P  20000202
                                            US 2000-179669P     P  20000202
                                            US 2000-179670P     P  20000202
                                            US 2000-179671P     P  20000202
                                            US 2000-179672P     P  20000202
                                            US 2000-179684P     P  20000202
                                            US 2000-179782P     P  20000202
                                            US 2000-179794P     P  20000202
                                            US 2001-775852      A1 20010202
                                            US 2001-776426      A3 20010202
                                            WO 2001-US3633      W  20010202
OTHER SOURCE(S):          CASREACT 135:166940; MARPAT 135:166940
GI
```



I



II



III

AB Taxanes I (R1 = H, OH; R2 = acyloxy; R3 = keto, hydroxy, acyloxy; R4 = carbamoyloxy, X1 = (un)substituted alkyl, alkenyl, alkynyl, Ph, heterocyclo; X2 = COX, CO2X, CONHX; X = hydrocarbyl, substituted hydrocarbyl, heterocyclo) were prepared as anticancer agents. Thus, 10-desacetylbaccatin III was protected as the 7,10-bis(carbobenzyloxy) derivative and treated with the azetidinone II followed by decarbobenzylation, reaction with EtNCO, and desilylation to give the docetaxel III. The in vitro cytotoxicity ID50 of III against HCT116 cells was <1 nM.

IT **181706-28-5P 352698-93-2P 352698-94-3P**
352698-95-4P 352698-96-5P 352698-97-6P
352698-98-7P 352698-99-8P 352699-00-4P
352699-01-5P 352699-02-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of C10 carbamoyloxy substituted taxanes as antitumor agents)

RN 181706-28-5 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-93-2 CAPLUS

CN 2-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-94-3 CAPLUS

CN 3-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-95-4 CAPLUS

CN 3-Thiophenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-96-5 CAPLUS

CN L-threo-Pentonic acid, 3,4,5-trideoxy-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-97-6 CAPLUS

CN 4-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-98-7 CAPLUS

CN 2-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-99-8 CAPLUS
CN 3-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352699-00-4 CAPLUS
CN 2-Thiophenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352699-01-5 CAPLUS
CN Cyclobutanepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352699-02-6 CAPLUS
CN Cyclopropanepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:581864 CAPLUS
DOCUMENT NUMBER: 135:152983
TITLE: Preparation and formulation of taxanes having improved solubility for pharmaceutical use as antitumor agents
INVENTOR(S): Holton, Robert A.
PATENT ASSIGNEE(S): Florida State University Research Foundation, Inc., USA
SOURCE: PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

```
     PATENT NO.          KIND  DATE      APPLICATION NO.        DATE
     ---------------     ----  --------  --------------------   --------
     WO 2001057013        A1   20010809  WO 2001-US3624         20010202
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2001034810        A5   20010814  AU 2001-34810          20010202
     US 2001051639        A1   20011213  US 2001-776492         20010202
     US 6649632           B2   20031118
     BR 2001004358        A    20020102  BR 2001-4358           20010202
     EP 1175414           A1   20020130  EP 2001-906972         20010202
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     US 2002052403        A1   20020502  US 2001-776426         20010202
     US 6638973           B2   20031028
     JP 2003521545        T2   20030715  JP 2001-556863         20010202
     NZ 514073            A    20040227  NZ 2001-514073         20010202
     ZA 2001006333        A    20020801  ZA 2001-6333           20010801
     NO 2001004752        A    20011127  NO 2001-4752           20011001
     US 2003060638        A1   20030327  US 2002-71924          20020206
     US 6750245           B2   20040615
     US 2004024051        A1   20040205  US 2003-609301         20030627
     US 2004034230        A1   20040219  US 2003-618063         20030711
     US 2004072872        A1   20040415  US 2003-676222         20031001
     US 2004097579        A1   20040520  US 2003-680649         20031007
     US 2004087547        A1   20040506  US 2003-720826         20031124
     US 2004122055        A1   20040624  US 2003-720615         20031124
     US 2004138267        A1   20040715  US 2003-743581         20031222
PRIORITY APPLN. INFO.:                   US 2000-179669P     P  20000202
                                         US 2000-179670P     P  20000202
                                         US 2000-179671P     P  20000202
                                         US 2000-179672P     P  20000202
                                         US 2000-179674P     P  20000202
                                         US 2000-179684P     P  20000202
                                         US 2000-179782P     P  20000202
                                         US 2000-179793P     P  20000202
                                         US 2000-179794P     P  20000202
                                         US 2001-775852     A1  20010202
                                         US 2001-775912     A1  20010202
                                         US 2001-776137     A1  20010202
```

US 2001-776274	A1	20010202
US 2001-776393	A1	20010202
US 2001-776426	A3	20010202
US 2001-776492	A1	20010202
US 2001-776494	A1	20010202
WO 2001-US3624	W	20010202

OTHER SOURCE(S): MARPAT 135:152983

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Taxanes, such as I [R7, R10 = H, acyl, carboxy, carbamoyl, etc.; X3 = alkyl, alkenyl, alkynyl, Ph, substituted Ph, heteroaryl; X5 = H, acyl, carboxyl, carboxamide, etc.] with improved solubility, were prepared for use as antitumor agents. Thus, taxotere analog II was prepared via esterification of baccatin III derivative III (R7 = COCH2Me, R10 = SiEt3) with β-lactam IV followed by a deprotection step using HF. The prepared taxanes were tested for cytotoxic activity against HCT116 cells. Pharmaceutical formulations of the prepared taxanes were also presented.

IT **181706-28-5P 352698-93-2P 352698-94-3P**
352698-95-4P 352698-96-5P 352698-97-6P
352698-98-7P 352698-99-8P 352699-00-4P
352699-01-5P 352699-02-6P 352699-04-8P
352699-05-9P 352699-06-0P 352699-07-1P
352699-08-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and formulation of taxanes having improved solubility for pharmaceutical use as antitumor agents)

RN 181706-28-5 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-93-2 CAPLUS

CN 2-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-94-3 CAPLUS

CN 3-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-95-4 CAPLUS

CN 3-Thiophenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-96-5 CAPLUS

CN L-threo-Pentonic acid, 3,4,5-trideoxy-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-97-6 CAPLUS

CN 4-Pyridinepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-98-7 CAPLUS

CN 2-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352698-99-8 CAPLUS
CN 3-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 352699-00-4 CAPLUS
CN 2-Thiophenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352699-01-5 CAPLUS
CN Cyclobutanepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352699-02-6 CAPLUS
CN Cyclopropanepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 352699-04-8 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 352699-05-9 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-4-nitro-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-
(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 352699-06-0 CAPLUS
CN 2-Furanpropanoic acid, α-hydroxy-β-[[(2E)-1-oxo-2-
butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-6-[[[(3,4-difluorophenyl)amino]carbonyl]oxy]-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester, (αR,βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 352699-07-1 CAPLUS
CN 2-Furanpropanoic acid, α-hydroxy-β-[[(2E)-1-oxo-2-
butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-
4a,8,13,13-tetramethyl-5-oxo-6-[[(phenylamino)carbonyl]oxy]-7,11-methano-
1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

```
L5   ANSWER 6 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN       (Continued)
```



```
RN   352699-08-2  CAPLUS
CN   2-Furanpropanoic acid, α-hydroxy-β-[[(2E)-1-oxo-2-
     butenyl]amino]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
     (benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12
     b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βR)- (9CI)  (CA
     INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.
```



```
REFERENCE COUNT:         22        THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
                                   RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L5   ANSWER 7 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:646001  CAPLUS
DOCUMENT NUMBER:          133:238151
TITLE:                    Preparation of taxoid compounds as osteogenesis
                          promoters
INVENTOR(S):              Ishizuya, Toshinori; Ikuta, Shunichi; Uzawa, Toyonobu;
                          Hori, Masayuki
PATENT ASSIGNEE(S):       Asahi Kasei Kogyo Kabushiki Kaisha, Japan
SOURCE:                   PCT Int. Appl., 152 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.          DATE
     ---------------     ----  --------      --------------------     --------
     WO 2000053592        A1   20000914      WO 2000-JP1334           20000306
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     JP 2003026673        A2   20030129      JP 1999-59415            19990305
PRIORITY APPLN. INFO.:                       JP 1999-59415         A  19990305
OTHER SOURCE(S):          MARPAT 133:238151
GI
```



I

```
AB   Claimed are osteogenesis promoters containing taxoids represented by general
     formula (I) in amts. effective for osteogenesis (wherein X and Y are each
     independently hydroxyl or a group convertible into hydroxyl in vivo; R1 is
     alkyl, alkenyl, alkynyl, Ph, naphthyl, furyl, or thienyl; R2 is alkyl, Ph,
     naphthyl, furyl, thienyl, alkoxy, or alkylamino; and R3 is hydrogen,
     alkyl, alkylcarbonyl, benzoyl, naphthoyl, furoyl, thenoyl, alkoxycarbonyl,
     or dialkylcarbamoyl) for the treatment of bone fracture and bone loss due
```

```
L5   ANSWER 7 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN       (Continued)
     to surgical bone removal.  Thus, de-N-benzoyl-3'-desphenyl-3'-
     isobutylpaclitaxel (prepn. given) was acylated by di-tert-amyl dicarbonate
     in a mixt. of EtOAc and satd. aq. NaHCO3 at room temp. for 5 h to give
     de-N-benzoyl-N-tert-amyloxycarbonyl-3'-desphenyl-3'-isobutylpaclitaxel
     (II).  II in vitro increased no. of bone nodules formed in rat
     osteoblastic cell from 5.3±5.2 (control) to 25, 64, and 97/well at 0.3,
     1, and 4 ng/mL, resp.
IT   178250-29-8P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of taxoid compds. as osteogenesis promoters for treatment of
        bone fracture and bone loss due to surgical bone removal)
RN   178250-29-8  CAPLUS
CN   Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-
     , (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-
     [[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
     dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)-  (9CI)  (CA INDEX NAME)

Absolute stereochemistry.  Rotation (-).
```



```
REFERENCE COUNT:         13        THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
                                   RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L5   ANSWER 8 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:547499  CAPLUS
DOCUMENT NUMBER:          133:150748
TITLE:                    Preparation of taxoid anti-tumor agents and
                          pharmaceutical compositions thereof
INVENTOR(S):              Ojima, Iwao
PATENT ASSIGNEE(S):       The Research Foundation of State University of New
                          York, USA
SOURCE:                   U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 330,956,
                          abandoned.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   5
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.          DATE
     ---------------     ----  --------      --------------------     --------
     US 6100411           A    20000808      US 1996-608003           19960304
     WO 9732578           A1   19970912      WO 1997-US2971           19970304
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN,
             YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
             ML, MR, NE, SN, TD, TG
     AU 9721374           A1   19970922      AU 1997-21374            19970304
     US 6096909           A    20000801      US 1997-910742           19970813
     US 6458976           B1   20021001      US 1999-457332           19991209
     US 2002022651        A1   20020221      US 2001-822842           20010402
     US 6500858           B2   20021231
     US 2003232878        A1   20031218      US 2002-330535           20021230
PRIORITY APPLN. INFO.:                       US 1994-330956        B2 19941028
                                             US 1996-608003        A  19960304
                                             WO 1997-US2971        W  19970304
                                             US 2001-822842        A3 20010402
OTHER SOURCE(S):          MARPAT 133:150748
GI
```

L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



I



II

AB Taxoids of formula I [R1 = alkyl, alkenyl; R2 = alkyl; R3, R4 = H, protecting group; R5 = H, acyl, alkoxycarbonyl, alkoxycarbamoyl; R6 = acyl] are prepared as antitumor agents. Thus, II was prepared and inhibited tumor growth against human tumor cell line A121 at IC50 = 0.37 nM, and MCF7-R at IC50 = 17 nM.

IT **178250-25-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of taxoid antitumor agents)

RN 178250-25-4 CAPLUS

CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **178250-29-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of taxoid antitumor agents)

RN 178250-29-8 CAPLUS

CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:531291 CAPLUS

DOCUMENT NUMBER: 133:290636

TITLE: Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages

AUTHOR(S): Kirikae, T.; Ojima, I.; Fuero-Oderda, C.; Lin, S.; Kirikae, F.; Hashimoto, M.; Nakano, M.

CORPORATE SOURCE: Dep. Infectious Dis. Tropical Med., Res. Inst., International Med. Cent. of Japan, Tokyo, Japan

SOURCE: FEBS Letters (2000), 478(3), 221-226

CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The antitumor agent, paclitaxel (Taxol®), mimics the actions of lipopolysaccharide (LPS) on murine macrophages (Mϕ). Various synthetic analogs of paclitaxel were examined for their potencies to induce nitric oxide (NO) and tumor necrosis factor (TNF) production by murine peritoneal Mϕ, and by human peripheral blood cells. The benzoyl group at C-2, the hydroxy group at C-7 and the acetyl group at C-10 were found to be critically important sites to activate murine Mϕ.

Nor-seco-taxoid analogs lacking the A ring of the taxane core of paclitaxel were inactive, but inhibit paclitaxel- or LPS-induced NO production

All the compds. tested did not induce TNF production by human blood cells.

IT **160084-79-7**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(structure activity relationship of paclitaxel analog for inducing nitric oxide and tumor necrosis factor production by murine macrophages)

RN 160084-79-7 CAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:488718 CAPLUS
DOCUMENT NUMBER: 133:266988
TITLE: Syntheses and biological activity of C-3'-difluoromethyl-taxoids
AUTHOR(S): Ojima, I.; Lin, S.; Slater, J. C.; Wang, T.; Pera, P.; Bernacki, R. J.; Ferlini, C.; Scambia, G.
CORPORATE SOURCE: Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY, 11794-340, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(7), 1619-1628
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of new taxoids bearing a difluoromethyl group at the C-3' position and modifications at the C-10 and C-14 positions was synthesized and their biol. activities studied. The in vitro cytotoxicity assay results indicated that these newly developed taxoids exhibited comparable to several times better activity against drug-sensitive cell line LCC6-WT, and 40-70 times better activity against the corresponding drug-resistant cancer cell line LCC6-MDR as compared to that of paclitaxel. Apoptosis anal. revealed the exceptional activity of SB-T 12843 (I) in inducing apoptosis in both MDR-bearing and MDR-neg. cancer cells.

IT **245658-06-4P**, SB-T 12841
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of C-3'-difluoromethyl taxoid derivs.)

RN 245658-06-4 CAPLUS

CN Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4,4-difluoro-2-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:405828 CAPLUS
DOCUMENT NUMBER: 131:272031
TITLE: Enantiopure fluorine-containing taxoids: potent anticancer agents and versatile probes for biomedical problems
AUTHOR(S): Ojima, Iwao; Inoue, Tadashi; Chakravarty, Subrata
CORPORATE SOURCE: Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA
SOURCE: Journal of Fluorine Chemistry (1999), 97(1-2), 3-10
CODEN: JFLCAR; ISSN: 0022-1139
PUBLISHER: Elsevier Science S.A.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fluorine-containing paclitaxel and docetaxel analogs are reported that are obtained through the coupling of enantiopure (3R,4S)-1-acyl-β-lactams with various baccatins. Some taxoids bearing the trifluoromethyl or difluoromethyl groups at the C-3' position possessed three orders of magnitude greater potency than either paclitaxel or doxorubicin against both sensitive and drug-resistant human breast cancer cell lines. The incorporation of fluorine in taxoids as a probe has been successfully exploited for the study of their metabolism and structure.
Fluorine-containing
taxoids are shown to block the metabolic pathways associated with the cytochrome P 450 class of enzymes. Structural studies using 19F and 1H NMR techniques on fluorine-containing taxoids in combination with mol. modeling have provided new insights into the biol. relevant conformations of taxoids in solution as well as in the microtubule-bound state.

IT **186819-43-2P 245658-06-4P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and cytotoxicity of enantiopure fluorine-containing taxoids)

RN 186819-43-2 CAPLUS

CN Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4,4,4-trifluoro-2-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 245658-06-4 CAPLUS

CN Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4,4-difluoro-2-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:652772 CAPLUS
DOCUMENT NUMBER: 127:293438
TITLE: Synthesis of novel 3'-trifluoromethyl taxoids through effective kinetic resolution of racemic 4-CF3-β-lactams with baccatins
AUTHOR(S): Ojima, Iwao; Slater, John C.
CORPORATE SOURCE: Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA
SOURCE: Chirality (1997), 9(5/6), 487-494
CODEN: CHRLEP; ISSN: 0899-0042
PUBLISHER: Wiley-Liss
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:293438
GI



I



II

AB The coupling of racemic 4-CF3-β-lactam (I) with various C-10 modified baccatins has resulted in CF3-taxoids (II) (R = H, Ac, Me2NCO, cyclopropanecarbonyl, MeO2C, 4-morpholinecarbonyl, EtCO, BuCO, Me3CCH2CO) with diastereoselectivities ranging from 9:1 to one single isomer. The observed high diastereoselectivity is ascribed to the highly efficient enantiomer-differentiation by the enantiopure lithium alkoxide of a baccatin III in the coupling reaction with a racemic 1-tBoc-β-lactam. These novel CF3-taxoids have also been shown to exhibit significant increases in activity against various cancer cell lines compared to either paclitaxel or docetaxel. In addition, the first asym. synthesis of a CF3-β-lactam via chiral ester enolate-imine cyclocondensation was performed with 50% enantioselectivity.

IT **186819-43-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 3'-trifluoromethyl taxoids through kinetic resolution of

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
racemic 4-CF3-β-lactams with baccatins)
RN 186819-43-2 CAPLUS
CN Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4,4,4-trifluoro-2-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:617970 CAPLUS
DOCUMENT NUMBER: 127:248260
TITLE: Preparation of taxoids as antitumor agents
INVENTOR(S): Ojima, Iwao
PATENT ASSIGNEE(S): Research Foundation of State University of New York, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

```
     PATENT NO.          KIND  DATE        APPLICATION NO.          DATE
     ---------------     ----  --------    ---------------------    --------
     WO 9732578           A1   19970912    WO 1997-US2971           19970304
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN,
             YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
             GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
             ML, MR, NE, SN, TD, TG
     US 6100411           A    20000808    US 1996-608003           19960304
     AU 9721374           A1   19970922    AU 1997-21374            19970304
PRIORITY APPLN. INFO.:                     US 1996-608003        A  19960304
                                           US 1994-330956        B2 19941028
                                           WO 1997-US2971        W  19970304
```

OTHER SOURCE(S): MARPAT 127:248260
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Taxoid compds. of formula I [R1 = alkyl, alkenyl, trifluoromethyl; R2 = alkyl; R3, R4 = H, protecting group; R5 = H, acyl, alkoxycarbonyl, carbamoyl; R6 = acyl] are prepared as antitumor agents. Thus, II was prepared via addition of 7-triethylsilylbaccatin III and III (preparation given), followed by deprotection. II showed IC50 of 0.90nM against ovarian cancer.

IT **178250-25-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of taxoid derivs. as antitumor agents)
RN 178250-25-4 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **178250-29-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of taxoid derivs. as antitumor agents)
RN 178250-29-8 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:123303 CAPLUS
DOCUMENT NUMBER: 126:157660
TITLE: Synthesis and biological activity of novel 3'-trifluoromethyl taxoids
AUTHOR(S): Ojima, Iwao; Slater, John C.; Pera, Paula; Veith, Jean M.; Abouabdellah, Ahmed; Begue, Jean-Pierre; Bernacki, Ralph J.
CORPORATE SOURCE: Department of Chemistry, State University of New York at Stony Brook, Stony Brook, NY, 11794-3400, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(2), 133-138
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Second generation taxoids possessing a trifluoromethyl moiety in place of the 3'-Ph group are synthesized by means of the β-Lactam Synthon Method. The in vitro cytotoxicities of these new taxoids are evaluated against several different human cancer cell lines and found to exhibit greatly enhanced activities as compared to those of paclitaxel and docetaxel. The activity enhancement is most remarkable against a drug-resistant breast cancer cell line, MCF7-R, expressing MDR phenotype.

IT **186819-43-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of novel 3'-trifluoromethyl taxoids)
RN 186819-43-2 CAPLUS
CN Butanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-4,4,4-trifluoro-2-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:20747 CAPLUS
DOCUMENT NUMBER: 126:60178
TITLE: Preparation of baccatin III derivatives as antitumors
INVENTOR(S): Terasawa, Hirofumi; Soga, Tsunehiko; Uoto, Koichi
PATENT ASSIGNEE(S): Daiichi Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 57 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253465	A2	19961001	JP 1995-58508	19950317

PRIORITY APPLN. INFO.: JP 1995-58508 19950317
OTHER SOURCE(S): MARPAT 126:60178
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted alkyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, OH, -CO-R9, etc.; R9 = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, etc.; R4 = H, OH, halo, alkyl; R5 = H, halo, alkyl; R6 = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, etc.; R7 = alkyl, aryl, alkoxy; R8 = H, OH] and their pharmaceutically acceptable salts, useful as antitumors, are prepared Thus, II was prepared in 5 steps from 10-deacetyl-7,10-bis-O-(triethylsilyl)baccatin III via oxidation, alkylation with MeI, reduction, reaction with (2S,3S)-N-(tert-butoxycarbonyl)-N,O-isopropylidene-3-phenylisoserine, and desilylation. In an in vitro study, II had a GI50 0.260 ng/mL against mouse leukemia cells P388.

IT **184645-48-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of baccatin III derivs. as antitumors)
RN 184645-48-5 CAPLUS
CN 2-Furanpropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-12b-(1-oxopropoxy)-6-[[[(2-pyridinylmethyl)amino]carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βR*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:544128 CAPLUS
DOCUMENT NUMBER: 125:237582
TITLE: Syntheses and Structure-Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells
AUTHOR(S): Ojima, Iwao; Slater, John C.; Michaud, Evelyne; Kuduk, Scott D.; Bounaud, Pierre-Yves; Vrignaud, Patricia; Bissery, Marie-Christine; Veith, Jean M.; Pera, Paula; Bernacki, Ralph J.
CORPORATE SOURCE: Department of Chemistry, State University of New York, Stony Brook, NY, 11794-3400, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(20), 3889-3896
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of new 3'-(2-methyl-1-propenyl) and 3'-(2-methylpropyl) taxoids with modifications at C-10 was synthesized by means of the β-lactam synthon method using 10-modified 7-(triethylsilyl)-10-deacetylbaccatin III derivs. The new taxoids thus synthesized show excellent cytotoxicity against human ovarian (A121), non-small-cell lung (A549), colon (HT-29), and breast (MCF-7) cancer cell lines. All but one of these new taxoids possess better activity than paclitaxel and docetaxel in the same assay, i.e., the IC50 values of almost all the taxoids are in the subnanomolar level. It is found that a variety of modifications at C-10 is tolerated for the activity against normal cancer cell lines, but the activity against a drug-resistant human breast cancer cell line expressing MDR phenotype (MCF7-R) is highly dependent on the structure of the C-10 modifier. A number of the new taxoids exhibit remarkable activity (IC50 = 2.1-9.1 nM) against MCF7-R. Among these, three new taxoids, SB-T-1213, SB-T-1214, and SB-T-1102, are found to be exceptionally potent, possessing 2 orders of magnitude better activity than paclitaxel and docetaxel. The observed exceptional activity of these taxoids may well be ascribed to an effective inhibition of P-glycoprotein binding by the modified C-10 moieties. The new taxoid SB-T-1213 (4a) shows an excellent activity (T/C = 0% at 12.4 and 7.7 mg/kg/dose, log10 cell kill = 2.3 and 2.0, resp.) against B16 melanoma in B6D2F1 mice via i.v. administration.

IT **178250-25-4P 178250-29-8P 181706-26-3P**
181706-27-4P 181706-28-5P 181706-29-6P
181706-30-9P 181706-31-0P 181706-32-1P
181706-34-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antitumor activity of C-10 modified taxoids)

RN 178250-25-4 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 178250-29-8 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 181706-26-3 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(diethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-27-4 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[(methylamino)carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181706-28-5 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(ethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-29-6 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-6-[[(propylamino)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(2R*,3S*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181706-30-9 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[[(1-methylethyl)amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absoluta stereochemistry.

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-31-0 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-6-[[(2-propenylamino)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(2R*,3S*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 181706-32-1 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, 12b-(acetyloxy)-12-(benzoyloxy)-6-[[(cyclohexylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(2R*,3S*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 181706-34-3 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, 12b-(acetyloxy)-12-(benzoyloxy)-6-[[(cyclohexylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(2R*,3S*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1996:394210 CAPLUS
DOCUMENT NUMBER:	125:58789
TITLE:	Taxoid derivatives, their preparation and their use as antitumor agents
INVENTOR(S):	Ojima, Iwao
PATENT ASSIGNEE(S):	Research Foundation of State University of New York, USA
SOURCE:	PCT Int. Appl., 43 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613495	A1	19960509	WO 1995-US13591	19951027
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9641330	A1	19960523	AU 1996-41330	19951027
EP 788493	A1	19970813	EP 1995-939561	19951027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10508022	T2	19980804	JP 1995-514660	19951027
US 6096909	A	20000801	US 1997-910742	19970813

PRIORITY APPLN. INFO.:

US 1994-330956	A	19941028
WO 1995-US13591	W	19951027

OTHER SOURCE(S): MARPAT 125:58789
GI



I

AB Taxoids I [R1 = alkyl, alkenyl; R2 = branched alkyl; R3, R4 = H, protecting group; R5 = H, acyl, alkoxylcarbonyl, carbamoyl; R6 = acyl] were prepared I are useful as antitumor agents or their precursors. Thus, 7-triethylsilylbaccatin III was treated with (3R,4S)-1-tert-butoxycarbonyl-3-triisopropylsilyloxy-4-(1-propenyl)azetidinone and deprotected to give 3'-dephenyl-3'-(1-propenyl)-10-acetyldocetaxel which had better antitumor activity against several cell lines than docetaxel.

IT **178250-25-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alkenyldephenyldocetaxels as neoplasm inhibitors)

L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 178250-25-4 CAPLUS
CN 4-Hexenoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **178250-29-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkenyldephenyldocetaxels as neoplasm inhibitors)
RN 178250-29-8 CAPLUS
CN Hexanoic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-[[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



```
L5   ANSWER 17 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN      (Continued)
```

```
L5   ANSWER 18 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         1995:46562  CAPLUS
DOCUMENT NUMBER:          122:56247
TITLE:                    A chemoselective approach to functionalize the C-10
                          position of 1-deacetylbaccatin III. Synthesis and
                          biological properties of novel C-10 Taxol analogs
AUTHOR(S):                Kant, Joydeep; O'Keeffe, Wendy S.; Chen, Shu-Hui;
                          Farina, Vittorio; Fairchild, Craig; Johnston, Kathy;
                          Kadow, John F.; Long, Byron H.; Vyas, Dolatrai
CORPORATE SOURCE:         Bristol-Myers Squibb Pharm. Res. Inst., Wallingford,
                          CT, 06492-7660, USA
SOURCE:                   Tetrahedron Letters (1994), 35(31), 5543-6
                          CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
GI
```



I



II

```
AB   A chemoselective approach to functionalize the C-10 position of
     10-deacetyl baccatin III (I), a key intermediate for the semi-synthesis of
     paclitaxel, is described.  The chemical provides an easy access to a variety
     of C-10 hydroxyl derivs., such as, ethers, esters, carbonates, carbamates,
     and sulfonates under mild conditions.  The C-10 modified baccatin derivs.
     were further employed in the synthesis of novel biol. active Taxol
     analogs, e.g. II (R1 = Ac, R2 = OCMe3).
IT   160084-79-7P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
```

```
L5   ANSWER 18 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN      (Continued)
        (prepn. and neoplasm-inhibiting activity of)
RN   160084-79-7  CAPLUS
CN   Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-,
     (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-6-
     [[(dimethylamino)carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
     dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-  (9CI)  (CA
     INDEX NAME)

Absolute stereochemistry.
```



```
L5   ANSWER 19 OF 19  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         1993:409005  CAPLUS
DOCUMENT NUMBER:          119:9005
TITLE:                    Preparation of O-carbamoyl taxol analogs as neoplasm
                          inhibitors
INVENTOR(S):              Bourzat, Jean Dominique; Commercon, Alain; Guenard,
                          Daniel; Gueritte-Voegelein, Francoise; Potier, Pierre
PATENT ASSIGNEE(S):       Rhone-Poulenc Rorer SA, Fr.
SOURCE:                   Eur. Pat. Appl., 18 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     EP 524093            A1    19930120    EP 1992-402046         19920716
         R:  PT
     FR 2679230           A1    19930122    FR 1991-8937           19910716
     FR 2679230           B1    19931119
     ZA 9205245           A     19930428    ZA 1992-5245           19920714
     WO 9302065           A1    19930204    WO 1992-FR687          19920716
         W:  AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE
     CA 2113074           AA    19930204    CA 1992-2113074        19920716
     AU 9223880           A1    19930223    AU 1992-23880          19920716
     EP 596010            A1    19940511    EP 1992-916744         19920716
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
     JP 06509107          T2    19941013    JP 1992-502629         19920716
     HU 66600             A2    19941228    HU 1994-113            19920716
     NO 9304723           A     19931220    NO 1993-4723           19931220
PRIORITY APPLN. INFO.:                      FR 1991-8937           19910716
                                            WO 1992-FR687          19920716
OTHER SOURCE(S):         MARPAT 119:9005
GI
```



I

```
AB   Title compds. [I; A = aryl; R = alkoxy, Ph, N-containing heterocyclyl, etc.;
     R1, R2 = H, CONR3R4; R3, R4 = H, (substituted) alkyl] were prepared  Thus, I
     (A = Ph, R = OCMe3) (II; R1 = R2 = CO2CH2CCl3) was condensed with
     H2N(CH2)3NMe2 and the product treated with Zn in HOAc-MeOH to give II [R1
     = CONH(CH2)3NMe2, R2 = H].  I were active against melanoma B16 in mice at
     1-10 mg/kg i.p.
IT   147375-23-3P 147375-26-6P 147375-28-8P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation and reaction of, in preparation of neoplasm inhibitors)
RN   147375-23-3  CAPLUS
```

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-6-[[[[3-(dimethylamino)propyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(.alpha.R*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)



RN 147375-26-6 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-6-[[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]oxy]-4-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 147375-28-8 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-6-[[[[3-(4-morpholinyl)propyl]amino]carbonyl]oxy]-5-oxo-4-[[(2,2,2-trichloroethoxy)carbonyl]oxy]-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **147359-36-2P 147359-37-3P 147359-39-5P**
147359-40-8P 147359-41-9P 147375-30-2P
147510-99-4P 147511-00-0P 147511-02-2P
147511-03-3P 147511-04-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as neoplasm inhibitor)

RN 147359-36-2 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-6-[[[[3-(dimethylamino)propyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, monohydrochloride, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)



● HCl

RN 147359-37-3 CAPLUS

CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, dihydrochloride, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●2 HCl

RN 147359-39-5 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-4,6-bis[[[[3-(dimethylamino)propyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, dihydrochloride, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)



●2 HCl

RN 147359-40-8 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4,6-bis[[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, tetrahydrochloride, [2aR-[2aα,4β,4aβ,6β,9α(.alpha.R*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●4 HCl

RN 147359-41-9 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-4,6-bis[[[[3-(4-morpholinyl)propyl]amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, dihydrochloride, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.alpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



●2 HCl

RN 147375-30-2 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-6-[[[[3-(4-morpholinyl)propyl]amino]carbonyl]oxy]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 147510-99-4 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-6-[[[[3-(dimethylamino)propyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)



RN 147511-00-0 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-6-[[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]oxy]-5-
oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,
[2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.a
lpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 147511-02-2 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-4,6-bis[[[[3-
(dimethylamino)propyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-
[2aα,4β,4aβ,6β,9α(αR*,βS*),11α
,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)



RN 147511-03-3 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-
tetramethyl-4,6-bis[[[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]oxy
]-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,
[2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.a
lpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 147511-04-4 CAPLUS
CN Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-
α-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-
tetramethyl-4,6-bis[[[[3-(4-morpholinyl)propyl]amino]carbonyl]oxy]-5-oxo-
7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,
[2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11.a
lpha.,12α,12aα,12bα]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



```
=> s us6706708/pn
L6            1 US6706708/PN

=> select l6
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E2 ASSIGNED

=> fil reg
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    97.18     257.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -13.30     -13.30

FILE 'REGISTRY' ENTERED AT 10:46:29 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 SEP 2004  HIGHEST RN 748739-98-2
DICTIONARY FILE UPDATES:  20 SEP 2004  HIGHEST RN 748739-98-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s e1-e2
              1 341498-08-6/BI
                  (341498-08-6/RN)
              1 62683-29-8/BI
                  (62683-29-8/RN)
L7            2 (341498-08-6/BI OR 62683-29-8/BI)

=> d l7 1-2
```

```
L7   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   341498-08-6  REGISTRY
CN   2,5-Pyrrolidinedione, 1-[[1-oxo-4-(2-pyridinyldithio)pentyl]oxy]- (9CI)
     (CA INDEX NAME)
FS   3D CONCORD
MF   C14 H16 N2 O4 S2
SR   CA
LC   STN Files:  CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or reagent)
RL.NP  Roles from non-patents:  RACT (Reactant or reagent)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               4 REFERENCES IN FILE CA (1907 TO DATE)
               4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
L7   ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   62683-29-8  REGISTRY
CN   Colony-stimulating factor (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Colony formation stimulating factor
CN   Colony stimulating activity
CN   Colony-stimulating glycoproteins
CN   CSF
CN   CSF (hormone)
CN   Neutrophil alkaline phosphatase-inducing factor
MF   Unspecified
CI   MAN
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
       BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, PHAR, PROMT, PROUSDDR,
       TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent;
       Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
       (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study); PREP (Preparation)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
            2226 REFERENCES IN FILE CA (1907 TO DATE)
              55 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            2226 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> s us6340701/pn
L8            0 US6340701/PN

=> fil caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         8.39     265.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00     -13.30

FILE 'CAPLUS' ENTERED AT 10:47:21 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Sep 2004  VOL 141 ISS 13
FILE LAST UPDATED: 20 Sep 2004  (20040920/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s us6340701/pn
L9            1 US6340701/PN

=> d l9
```

```
L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:396857  CAPLUS
DN   135:492
TI   Cytotoxic agents comprising taxanes conjugated to cell-binding agents, and
     their therapeutic use
IN   Chari, Ravi V.; Blattler, Walter A.
PA   Immunogen, Inc., USA
SO   PCT Int. Appl., 65 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE       APPLICATION NO.        DATE
     ---------------     ----   --------   --------------------   --------
PI   WO 2001038318        A1    20010531   WO 2000-US30149        20001121
         W:  AU, CA, JP, NZ
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     EP 1242401           A1    20020925   EP 2000-982077         20001121
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2003514903        T2    20030422   JP 2001-540081         20001121
     AU 765588            B2    20030925   AU 2001-19149          20001121
     NZ 517772            A     20040326   NZ 2000-517772         20001121
     US 6340701           B1    20020122   US 2000-717026         20001122 <--
     US 2002013485        A1    20020131   US 2001-933018         20010821
     US 6372738           B2    20020416
     US 2002086897        A1    20020704   US 2002-59022          20020130
     US 6436931           B2    20020820
     US 2003004210        A1    20030102   US 2002-207814         20020731
     US 6706708           B2    20040316
     US 2004087649        A1    20040506   US 2003-684746         20031015
PRAI US 1999-167228P      P     19991124
     WO 2000-US30149      W     20001121
     US 2000-717026       A3    20001122
     US 2001-933018       A3    20010821
     US 2002-59022        A3    20020130
     US 2002-207814       A3    20020731
OS   MARPAT 135:492
RE.CNT  9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
=> select l9\
L9\ IS NOT A VALID L-NUMBER
The L-number entered is not in the range of valid L-numbers.

=> select l9
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E3 THROUGH E4 ASSIGNED

=> fil caplus
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        3.40     269.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)           SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                        0.00     -13.30

FILE 'CAPLUS' ENTERED AT 10:48:01 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Sep 2004  VOL 141 ISS 13
FILE LAST UPDATED: 20 Sep 2004  (20040920/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s e3
L10           4 341498-08-6/BI

=> s e4
L11        2226 62683-29-8/BI

=> d l10 1-4
```

```
L10  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:551336  CAPLUS
DN   139:106431
TI   Methods for preparing immunoconjugates
IN   Mazzola, Gergory L.; Wang, William K.; Zapata, Gerardo A.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 18 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.        DATE
     ---------------     ----   --------     --------------------   --------
PI   WO 2003057163        A2    20030717     WO 2003-US205          20030102
     WO 2003057163        A3    20030918
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
             ML, MR, NE, SN, TD, TG
PRAI US 2002-345305P      P     20020103
```

```
L10  ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:880426  CAPLUS
DN   138:100513
TI   Tumor-Specific Novel Taxoid-Monoclonal Antibody Conjugates
AU   Ojima, Iwao; Geng, Xudong; Wu, Xinyuan; Qu, Chuanxing; Borella,
     Christopher P.; Xie, Hongsheng; Wilhelm, Sharon D.; Leece, Barbara A.;
     Bartle, Laura M.; Goldmacher, Victor S.; Chari, Ravi V. J.
CS   Department of Chemistry, State University of New York at Stony Brook,
     Stony Brook, NY, 11794-3400, USA
SO   Journal of Medicinal Chemistry (2002), 45(26), 5620-5623
     CODEN: JMCMAR; ISSN: 0022-2623
PB   American Chemical Society
DT   Journal
LA   English
RE.CNT  34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L10  ANSWER 3 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:655114  CAPLUS
DN   137:201187
TI   Process for preparation of cytotoxic conjugates of maytansinoids and cell
     binding agents
IN   Chari, Ravi V. J.; Widdison, Wayne C.
PA   Immunogen, Inc., USA
SO   U.S., 17 pp.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.        DATE
     ---------------     ----   --------     --------------------   --------
PI   US 6441163           B1    20020827     US 2001-867598         20010531
     WO 2002098883        A1    20021212     WO 2002-US3378         20020214
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1390370           A1    20040225     EP 2002-720913         20020214
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004520450        T2    20040708     JP 2003-502004         20020214
     US 2003055226        A1    20030320     US 2002-161651         20020605
PRAI US 2001-867598       A     20010531
     WO 2002-US3378       W     20020214
OS   CASREACT 137:201187; MARPAT 137:201187
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
L10  ANSWER 4 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:396857  CAPLUS
DN   135:492
TI   Cytotoxic agents comprising taxanes conjugated to cell-binding agents, and
     their therapeutic use
IN   Chari, Ravi V.; Blattler, Walter A.
PA   Immunogen, Inc., USA
SO   PCT Int. Appl., 65 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.        DATE
     ---------------     ----   --------     --------------------   --------
PI   WO 2001038318        A1    20010531     WO 2000-US30149        20001121
         W:  AU, CA, JP, NZ
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
     EP 1242401           A1    20020925     EP 2000-982077         20001121
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2003514903        T2    20030422     JP 2001-540081         20001121
     AU 765588            B2    20030925     AU 2001-19149          20001121
     NZ 517772            A     20040326     NZ 2000-517772         20001121
     US 6340701           B1    20020122     US 2000-717026         20001122
     US 2002013485        A1    20020131     US 2001-933018         20010821
     US 6372738           B2    20020416
     US 2002086897        A1    20020704     US 2002-59022          20020130
     US 6436931           B2    20020820
     US 2003004210        A1    20030102     US 2002-207814         20020731
     US 6706708           B2    20040316
     US 2004087649        A1    20040506     US 2003-684746         20031015
PRAI US 1999-167228P      P     19991124
     WO 2000-US30149      W     20001121
     US 2000-717026       A3    20001122
     US 2001-933018       A3    20010821
     US 2002-59022        A3    20020130
     US 2002-207814       A3    20020731
OS   MARPAT 135:492
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       8.32     277.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -13.30

FILE 'REGISTRY' ENTERED AT 10:48:25 ON 21 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    20 SEP 2004  HIGHEST RN 748739-98-2
DICTIONARY FILE UPDATES:   20 SEP 2004  HIGHEST RN 748739-98-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s e3
L12            1 341498-08-6/BI
                   (341498-08-6/RN)

=> s e4
L13            1 62683-29-8/BI
                   (62683-29-8/RN)

=> d l12
```

```
L12  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   341498-08-6  REGISTRY
CN   2,5-Pyrrolidinedione, 1-[[1-oxo-4-(2-pyridinyldithio)pentyl]oxy]- (9CI)
     (CA INDEX NAME)
FS   3D CONCORD
MF   C14 H16 N2 O4 S2
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or reagent)
RL.NP  Roles from non-patents:  RACT (Reactant or reagent)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               4 REFERENCES IN FILE CA (1907 TO DATE)
               4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> d l13
```

```
L13  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   62683-29-8  REGISTRY
CN   Colony-stimulating factor (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Colony formation stimulating factor
CN   Colony stimulating activity
CN   Colony-stimulating glycoproteins
CN   CSF
CN   CSF (hormone)
CN   Neutrophil alkaline phosphatase-inducing factor
MF   Unspecified
CI   MAN
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS,
       BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, PHAR, PROMT, PROUSDDR,
       TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent;
       Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
       (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  BIOL (Biological
       study); PREP (Preparation)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
            2226 REFERENCES IN FILE CA (1907 TO DATE)
              55 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            2226 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> log y
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
FULL ESTIMATED COST                                     3.96    281.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE     TOTAL
                                                       ENTRY   SESSION
CA SUBSCRIBER PRICE                                     0.00    -13.30

STN INTERNATIONAL LOGOFF AT 10:48:51 ON 21 SEP 2004
```